Boston Scientific Corporation strengthened its position in the interventional cardiovascular market by acquiring Israel-based startup SoniVie, maker of the TIVUS intravascular ultrasound system. The device is intended to treat hypertensive disorders, a leading risk factor for cardiovascular disease, with ultrasound nerve ablation.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?